Key facts
- Notable investors include Tech Incubator Program for Startup, Premier Partners, DAYLI Partners, Meritz Securities, BSK Investment — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for FNCT Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for FNCT Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FNCT Biotech
Developer of antibody therapeutics designed to treat idiopathic pulmonary fibrosis (IPF). The company's platform uses genetic engineering to create antibodies that target the underlying cause of IPF, providing the healthcare industry with a new treatment option for patients with this medical need.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2021
- Employees
- 9
- Website
- fnctbiotech.com/
- Ownership
- Privately Held (backing)
FNCT Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FNCT Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FNCT Biotech in its N-PORT filings yet. We sweep new filings monthly.